S. Deaglio et al., Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells, LEUK RES, 25(3), 2001, pp. 227-235
Exposure of RPMI 8226, Karpas 707 and U266 human myeloma-like lines to low
doses of As2O3 was followed by a marked increase in lymphokine activated ki
llers (LAK)-mediated killing and up- modulation of CD38 and CD54, two molec
ules involved in cell-cell interactions. Moreover: simultaneous exposure of
effecters and targets to As2O3 yielded the most effective condition for ly
sis. The expression of CD31 (CD38 ligand) and CD11a (CD54 ligand) was also
up-regulated by LAK, suggesting that increased adhesion was responsible for
the improved killing. Similar results were obtained using freshly isolated
myeloma cells. These findings indicate that As(2)O2(3) may be useful to bo
ost the immune system against myelomas. (C) 2001 Elsevier Science Ltd. All
rights reserved.